The Cancer Stem Cells (CSCs) theory suggests that genetic alterations in stem cells are the direct cause for cancer. The evidence for a CSC population that results in pituitary tumors is poor. Some studies report the isolation of CSCs, but a deep characterization of the stemness of these cells is lacking. Here, we report the isolation and detailed characterization of progenitor mesenchymal cells (PMCs) from both growth hormone-secreting (GH + ) and non-secreting (NS) pituitary adenomas, determining the immunophenotype, the expression of genes related to stemness or to pituitary hormone cell types, and the differentiative potential towards osteo-, chondro-and adipogenic lineages. Finally, the expression of CD133, known as a marker for CSCs in other tumors, was analyzed. Isolated cells, both from GH + and NS tumors, satisfy all the criteria for the identification of PMCs and express known stem cell markers (OCT4, SOX2, KLF4, NANOG), but do not express markers of pituitary hormone cell types (PITX2, PROP1, PIT1). Finally, PMCs express CD133. We demonstrated that pituitary tumors contain a stem cell population that can generate cell types characteristic of mesenchymal stem cells, and express CD133, which is associated with CSCs in other tumors.
INTRODUCTION
The pituitary gland is a central regulator in the endocrine system, controlling metabolism, reproduction, stress response, growth and other physiological processes through the secretion of specific hormones. Pituitary adenomas are uncommon although their incidence is rising (up to 25% in unselected autopsy series and radiological studies). 1 The majority of pituitary adenomas is benign and slow growing, but in some cases, they are locally aggressive and atypical. Pituitary carcinoma is relatively rare, occurring in less than 0.1% of pituitary tumors. Pituitary tumors can vary in size and behavior. The problems caused by pituitary tumors are related to either the hormones they secrete or the effects of an expanding sellar mass. Pituitary tumors are classified based on the cell type that predominates within the adenoma. Adenomas that do not produce hormones are named non-secreting (NS) pituitary adenomas. The clinical features of NS adenomas are typically caused by sellar mass effects, including headaches and vision loss. Pituitary tumors that secrete hormones can cause clinical features associated with the specific hormone secreted. For instance, growth hormonesecreting pituitary adenomas (GH + ) cause acromegaly and account for about 20% of all primary pituitary tumors. Although monoclonal in nature, the underlying pathogenesis of pituitary tumors is poorly understood. 2 In the past few years, the introduction of the cancer stem cell (CSC) theory opened new perspectives for the diagnosis and cure of solid tumors. The concept that a specific subpopulation of tumor cells possessing distinct stem cell properties 3, 4 implies that CSCs arise as an intrinsic property of tumor biology and development. These CSCs are characterized by the expression of transcription factors, including SOX2, OCT4, KLF4 and NANOG, which are also expressed in other, untransformed stem cell populations. 5 CSCs are proposed to persist in tumors as a distinct population and cause relapse and metastasis by giving rise to new tumors.
The existence and the role of CSCs in benign pituitary adenomas is controversial. Other authors 6 report the isolation of sphere-forming stem-like cells from pituitary tumors that produce pituitary hormone-secreting cell types. The tumor stem cells were isolated from one GH-secreting pituitary adenoma and one NS tumor, leaving the prevalence of potential CSCs in pituitary adenomas unexamined. However, the use of a neuro-sphere formation procedure to isolate stem cells from the adenomas limits the potential range of cell types that can be characterized from the adenoma. The Mesenchymal and Tissue Stem Cell Committee of the International Society for Cellular Therapy proposed minimal criteria to define human mesenchymal stem cells (MSCs). 7 First, MSCs must be plastic-adherent when maintained in standard culture conditions. Second, MSCs must express CD105, CD73 and CD90, and lack expression of CD45, CD34, CD14 or CD11b, CD19 and HLA-DR surface molecules. Third, MSCs must differentiate to osteoblasts, adipocytes and chondroblasts in vitro. Here, we report the isolation and detailed characterization of progenitor mesenchymal cells (PMCs) from both GH + and NS pituitary adenomas, demonstrating that pituitary tumors contain a stem cell population.
We collected biopsies from six human tumors (three GH + and three NS) and used them to isolate and characterize stem cells according to the criteria identified by Dominici, further adding the expression of known stem cells markers (OCT4, SOX2, KLF4 and NANOG). The isolated stem cells were then characterized by the expression of differentially activated genes that characterize PMCs. Finally, we found that the MSCs isolated from the pituitary adenomas also express the transmembrane glycoproteine CD133 (Prominin-1), an important, although not exclusive, biomarker of CSCs. 8 
MATERIALS AND METHODS Patients
Six patients with pituitary macroadenomas, three with GH + and three with NS tumors based on clinical evaluation and biochemical workup, who underwent transsphenoidal pituitary surgery, were enrolled in the present study. All patients were negative for pituitary tumors within their family and therefore considered as sporadic. Clinical characteristics of patients are reported in Table 1 . Written informed consent was obtained from all patients and the study was approved by local ethics committees and conducted in accordance with the Declaration of Helsinki.
Each adenoma was immunohistochemically stained for six pituitary hormones (GH, PRL, ACTH, FSH, LH and TSH) using commercial antibodies. In acromegalic patients, 'Pure' GH cell adenomas were confirmed by immunohistochemical study after excluding adenomas containing 5% or more prolactin-positive cells; specifically, one adenoma was classified as densely granulated (case 1), and two others as sparsely granulated (case 2 and 3). NS tumors did not exhibit staining for any of the hormones or had only weak scattered staining, and were classified as null cell adenomas. Tumors biopsies, with a thickness of 1 mm, were collected into two different tubes: one biopsy was used for progenitor cells isolation and the other for RNA extraction.
Progenitor mesechymal cells (PMCs) isolation from pituitary tumors
On the basis of our previous experience in MSCs isolation, [9] [10] [11] [12] the tumor biopsies were mechanically minced up into a suspension and then transferred into six-well plates for culturing in DMEM/F12 medium (Lonza Group Ltd, Basel, Switzerland) supplemented with 10% fetal bovine serum (Lonza). Cell morphology was evaluated by phase contrast microscopy (Leica DM IL; Leica Microsystems GmbH, Wetzlar, Germany) and the viability was assessed by an automated cell counter (Invitrogen, Milan, Italy) and by the colorimetric MTT assay (Merck-Millipore, Darmstadt, Germany). All tests were performed in triplicates and the OD values were expressed as mean ± s.d. for the two subgroups (GH + and NS). To examine doubling time, the cells were seeded at a density of 5 × 10 3 cells cm −2 , and the doubling time of the harvested cells was calculated using an algorithm available online (http://www.doubling-time.com):
where N0 is the number of cells inoculated, Nt is the number of cells harvested and t is the culture time in hours. 13 Data are expressed as mean ± s.d. for the two subgroups (GH + and NS). GH secretion in the culture medium was evaluated from day 0 (day of sample collection) up to day 10 by chemiluminescent immunoassay (Diagnostic Products Corporation, Los Angeles, CA, USA); sensitivity thresholds for GH values were 0.04 ng ml − 1 .
Stemness characterization
For all experiments, exponentially growing cells at the third passage and at a confluence of about 75% were used. The stemness of isolated cells was assayed following the minimal criteria for the identification of human MSCs defined by Dominici, 7 which required immunophenotypical characterization by cytofluorimetric analysis and the assessment of differentiative potential towards oste-, chondro-and adipogenic lineages by appropriate staining techniques. For immunophenotyping, 2.5 × 10 5 cells were stained for 45 min with fluorescin isothiocyanate-conjugated antibodies (Becton Dickinson, Milan, Italy) against: HLA-DR, CD14, CD19, CD34, CD45, CD73, CD90 and CD105. As it is reported 14 that many of the mesenchymal markers are also found in fibroblasts, we analyzed the level of CD9 (Becton Dickinson), which is differently expressed by the two cellular subsets. Differentiation into osteocytes, chondrocytes and adipocytes was assessed using STEMPRO Osteogenesis, Chondrogenesis and Adipogenesis Kits (GIBCO, Life Technologies, Monza, Italy), respectively. Cells cultured in DMEM/F-12 with 10% fetal bovine serum were used as negative controls.
Osteogenic differentiation was assessed by Von Kossa and alkaline phosphatase staining; adipogenic differentiation was tested by Oil Red staining.
For chondrogenesis, cells were cultured in a pellet culture system and sections were exposed to a solution of Safranin-O.
In addition, we assayed a panel of genes related to self-renewal and multipotency (OCT4, NANOG, KLF4, SOX2) using quantitative reverse transcription PCR (qRT-PCR). MSCs isolated from amniotic fluid (AF-MSCs) were used as positive control for stem cell and RNA extracted directly from two tumor biopsies (one GH + and one NS) of the same patients as control for differentiated cells. AF-MSCs are pluripotent, and trail only embryonic stem cells in their capacity to generate different tissues. We have previously characterized the pluripotency of AF-MSCs. [15] [16] [17] Total RNA was extracted from isolated cells or tumor tissues using the PerfectPure RNA Cell & Tissue kit (5 PRIME, Hamburg, Germany). One microgram of total RNA was reverse-transcribed with Masterscript RT-PCR System kit (5 PRIME). PCR analysis was performed using EVA Green PCR Master Mix (Bio-Rad, Milano, Italy) and a Master Cycle (Eppendorf, Milan, Italy) instrument. All samples were tested in triplicate with the reference genes GAPDH and β-ACTIN for data normalization. Of the two, GAPDH gave the most consistent results and was therefore used. After amplification, melting curves were acquired. Direct detection of PCR products was monitored by measuring the fluorescence produced by SYBR Green I dye (EVA Green PCR Master Mix, Bio-rad) binding to double strand DNA after every cycle. These measurements were then plotted against cycle numbers. The parameter threshold cycle (Ct) was defined as the cycle number at which the first detectable increase above the threshold in fluorescence was observed.
Quantification of mRNA expression was calculated by the 2 − ΔΔCt method, 18 where ΔCt-Ct (gene of interest)-Ct (control gene) and Δ (ΔCt) = ΔCt (isolated cells)-ΔCt (tumor tissue). Data from tumor tissues are expressed equal to 1 (reference level). The expression values for the genes of interest are reported as the mean ± s.d. for the two subgroups (GH + and NS) of pituitary adenomas and for AF-MSCs over three independent experiments. Primer sequences are listed in Table 2 .
After testing the presence of OCT4, NANOG, KLF4 and SOX2 at mRNA level, we investigated by cytofluorimetric analysis, as above-described, the 
Pituitary mRNA expression in PMCs by qRT-PCR
The PMCs were examined for markers of pituitary hormone-secreting cell types using qRT-PCR as above. The genes examined were PITX2 (Pituitary homeobox 2), PROP1 (Prophet of Pit-1) and PIT1 (Pituitary-specific transcription factor 1). [19] [20] [21] [22] For comparison, RNA extracted directly from two tumor biopsies (one GH + and one NS) of the same patients was used as a positive control. The expression levels from the tumor biopsy tissue were expressed equal to 1 (reference level). The values of the expression of genes of interest are referred as mean ± s.d. for the two subgroups (GH + and NS), over three independent experiments. Primer sequences are listed in Table 2 .
Western blot and cytofluorimetric analysis for CD133 . As endogenous control, the membrane was incubated with mouse anti-human β-ACTIN antibody (Santa Cruz Biotechnology). To confirm the expression of CD133 and to evaluate the percentage of positive cells, a cytofluorimetric analysis by using anti-CD133 antibody (Santa Cruz Biotechnology) was performed, as above-described.
Transwell migration assay
Cells (10 7 ) derived from one GH + and one NS adenoma were subjected to positive selection by using Dynabeads sheep anti-mouse IgG (Invitrogen) in combination with primary mouse antibodies anti-human CD133 (Santa Cruz Biotechnology) following the manufacturer's instructions. Unbound cells (CD133 − ) were used as control. CD133 + and CD133 − cells (2 × 10 5 ) were resuspended in 200 μl of serum-free medium (DMEM/F12) and seeded on the top chamber of the 8 μm pore, 6.5 mm polycarbonate transwell filters (Corning, New York, USA). The full medium (600 μl) containing 10% fetal bovine serum was added to the bottom chamber. The cells were allowed to migrate for 24 h at 37 C in a humidified incubator with 5% CO 2 . The inserts were then taken away and nonmigratory cells were removed from the upper chamber by gentle scraping. The cells attached to the lower surface of membrane were fixed in 4% paraformaldehyde at room temperature for 30 min, stained with 4,6diamidino-2-phenylindole (Sigma), and the number of cells on the lower surface of the filters was counted in five different fields under the microscope.
Statistics
To test the significance of the variations regarding proliferation rate and mRNA expression among samples, statistical analyses were performed with paired-sample t-test or non-parametric Wilcoxon Signed-Ranks tests, depending on the normal distribution of the means tested by the Shapiro-Wilk-test. P-values less than 0.05 were considered significant.
RESULTS
Isolation and characterization of PMCs derived from GH+ and NS pituitary tumors PMCs) were obtained from six biopsies (three GH + and three NS) of pituitary tumors. No significant differences in morphology ( Figure 1a ) or proliferation rate (Figure 1b ), as measured by MTT test, were noted among the six samples. In addition, doubling times for firstto twelfth-passage were determined for the isolated cells. The doubling times, for all tested samples, were almost stable for the first 8 passages, (about 18 ± 1 h and 19 ± 2 h for PMCs derived from GH + and from NS tumors, respectively), and gradually increased to 40 ± 3 h and 39 ± 2 h up to passage 12 (Figure 1c ). GH secretion was evaluated in the culture medium from day 0 (day of sample collection) up to day 10 by chemiluminescent immunoassay. As expected, cells derived from NS tumors never secreted GH; PMCs from GH + adenomas revealed a decreasing secretion of GH for the first 5 days; after this period, the secretion of GH hormone was no more detectable. This result may mean that, during culture, cells are going towards undifferentiated status. Cytofluorimetric analysis revealed that isolated cells were strongly positive for CD73, CD90 and CD105 and negative for HLA-DR, CD14, CD19, CD34 and CD45 (Table 3) , indicating a mesenchymal-like immunophenotype. Cells derived from the six biopsies all were 93-99% positive for CD73, CD90 and CD105, and less than 2% positive for HLA-DR, CD14, CD19, CD34 and CD45. CD9, used as distinguishing marker between mesenchymal cells and fibroblasts, was negative for isolated cells, confirming that these cells were not fibroblasts. The ability to differentiate into all of the mesenchymal lineages was tested in cells derived from both GH-secreting and NS tumors. The differentiative potential of both sets of putative PMCs was the same and proceeded at the same rate. Osteogenic differentiation was detected after 10 days, when cells were strongly positive for alkaline phosphatase (Figure 2a ) and Von Kossa staining, demonstrating aggregates of mineralized matrix (Figure 2b ). Differentiation into adipocytes occurred after 15 days, as evidenced by the accumulation of lipid vacuoles within the cytoplasm (Figure 2c ). Chondrogenic differentiation was achieved after 30 days, as shown by Safranin-O staining (Figure 2d ). These results demonstrate that the cells isolated from the pituitary adenomas meet the criteria for progenitor mesenchymal cells.
PMCs-NS
To further characterize these PMCs, the expression of the stem cell markers OCT4, NANOG, KLF4 and SOX2 was tested by qRT-PCR. AF-MSCs were used as control for known stem cells and pituitary tumor biopsies were used as control of differentiated cells. The expression levels of the stem cell markers were higher in the PMCs than tumor biopsies, indicating that the PMCs express stem cell markers, although the expression levels were not as high as for the AF-MSCs (Figure 3a ). In addition, the presence of OCT4, NANOG, KLF4 and SOX2 at protein level was evaluated by cytofluorimetric analysis. The histograms (Figure 3b ) showed as the proteins were expressed by almost the totality of the cells (the positivity was higher than 92%), with no differences between GH + and NS PMCs.
Characterization of pituitary hormone cell types
The hormone-expressing cells of the pituitary anterior lobe are characterized by a series of transcription factors during development. The earliest pituitary progenitor cells express PITX2, which is then maintained in the thyrotropes and gonadotropes of the adult Table 3 . Flow cytometry results of PMCs
PMCs-GH+
PMCs-NS gland. PROP1 is expressed in the pituitary progenitors and during embryogenesis and is required for the development of somatotropes, lactotropes and thyrotropes. PIT1 is expressed after PROP1 during embryogenesis and is maintained in the adult gland in the somatotropes, lactotropes and thyrotropes. We examined the expression of these genes in the PMCs in comparison with the expression in tissue taken from the tumor biopsies and found that the PMCs do not express these pituitary hormone-specific genes.
These results indicate that the PMCs are not differentiating into pituitary hormone cell types.
Cancerogenic features of the isolated cells CD133 is a transmembrane glycoprotein that is expressed in both normal and cancerous stem cells. The expression of CD133 is sometimes used as a marker of cancerous stem cells; however, its use is controversial 23, 24 . We sought to determine the expression of CD133 in the GH + and NS PMCs by western blot and cytofluorimetric analysis. A reactive band of 120 KDa was detected in all samples with the same intensity, indicating that the PMCs express CD133. A representative experiment with one GH + sample and one NS sample is shown in Figure 4a with β-actin as the control.
To evaluate the percentage of cells expressing CD133, a cytofluorimetric analysis was performed; it revealed that about 4-5% of cells were positive for CD133 ( Figure 4b ). Cancer cells are characterized by their metastatic activity. To determine whether PMCs might have metastatic potential, we performed a transwell migration assay. CD133 + cells were isolated using magnetic beads and placed on a transwell filter and the migratory behavior was assessed compared with CD133 − cells. After 24 h the CD133 + cells had a significantly higher percentage of migratory cells, indicating the potential for metastatic activity. CD133 + cells from both GH + and NS PMCs displayed similar levels of migratory aptitude (Figure 4c ).
DISCUSSION
Previous studies report the isolation of stem-like cells from pituitary adenomas by a neuro-sphere formation method or by CD133 detection (together with CD34) in fixed samples. 6, [25] [26] [27] The stem cells isolated by neuro-sphere formation have the capacity to form secreting and NS cell types characteristic of a pituitary adenoma. The International Society for Cellular Therapy has published specific criteria under which cells can be considered MSCs. The use of the neuro-sphere methodology to isolate stem cells from pituitary adenomas does not adhere to these criteria and leaves unexamined the potential that pituitary adenomas may contain MSCs. Here, we isolated cells from three GH + and three NS pituitary adenomas and performed experiments to clearly define them as PMCs. Our results demonstrate that the isolated cells have a stem-like immunophenotype and contain the ability to differentiate into osteo-, chondro-and adipolineages. Subsequently, we improved the characterization of the PMCs by determining a partial transcriptional profile of the isolated cells. The pituitary PMCs express genes and proteins related to selfrenewal and pluripotency, including OCT4, NANOG, KLF4 and SOX2. AF-MSCs are well characterized stem cells with a high degree of pluripotency. 28 Pituitary PMCs do not express stem cell markers to the same degree as AF-MSCs, but have a significant increase in stem cell marker expression compared with differentiated pituitary tissues, indicating that pituitary PMCs have a transcriptional profile similar to known stem cells. The pituitary PMCs also do not express transcription factors characteristic of differentiating pituitary hormone-secreting cell types, indicating that the PMCs are not actively differentiating into hormonesecreting cell types. The use of immunophenotyping, assays of differentative potential and gene expression analysis allow us to confidently describe the pituitary adenoma isolated cells as PMCs.
Our analysis of the mesenchymal differentiative potential does not address whether or not the PMCs can give rise to pituitary hormone-secreting cell types. The use of a neuro-sphere methodology to isolate stem cells from pituitary adenomas does not asses the mesenchymal differentiative potential of the stem cells. It should be noted that we cannot determine whether pituitary adenomas contain one stem cell population with the capacity to form both hormone-secreting and mesenchymal cell types or whether pituitary adenomas contain two separate populations of stem cells that separately form hormone-secreting and mesenchymal cell types of the tumor. Further research is necessary to differentiate between these two possibilities.
The pituitary gland is a highly vascularized tissue, and the endothelial and pericyte cells that comprise the vasculature of the head, including the pituitary gland, arise from definitive mesoderm and neural crest. [29] [30] [31] The definitive mesoderm-derived endothelial cells and neural crest-derived pericytes are more likely to produce a mesenchyme-like stem cell than a pituitary stem cell. We have shown that the pituitary PMCs do not express CD34, an endothelial cell marker at passage three, suggesting that the PMCs do not arise from endothelial cells in the pituitary tumor. The origin of MSCs during embryogenesis has not been resolved, with Representative FACScan analyses of expression of CD133 in GH + PMCs; no significant differences were noted between GH + -and NS-derived PMCs. Solid gray fluorescence histograms, negative control (FITC-labeled IgG1 isotype control). (c) After selection using magnetic beads, cells (derived from one GH + and one NS adenoma) were subjected to transwell migration assay. Cells of five different fields were counted and expressed as percentage of the total. Three independent experiments were performed. *P o0.001 some reports describing a pericyte origin and others describing a neural crest origin. 32 In the head where pericytes are neural crest-derived, 30, 31 MSCs are likely to originate from neural crest cells. Neural crest derivatives of any kind have not demonstrated the capacity to generate pituitary hormone-secreting cell types. Therefore, we favor the possibility that two different stem cell populations exist within a pituitary tumor, and that they can be separately isolated using two established methodologies. Neurosphere formation favors the isolation of pituitary stem cells, whereas isolation of plastic adherent stem cells favors isolation of PMCs. Neural crest lineage-tracing experiments in mice could confirm the possibility the pituitary PMCs are of neural crest origin. CD133 is a transmembrane glycoprotein that is expressed in many solid tumors. [33] [34] [35] As such, it has gained favor as a CSC marker. However, CD133 is also expressed in normal stem cells and epithelia 8 and so the expression of CD133 does not indicate that a cellular population has undergone transformation. We chose to determine the expression of CD133 in the pituitary PMCs to potentially expand the range of known cell types that express this glycoprotein. We found that 5% of the pituitary PMCs expresses CD133. Migratory behavior is a hallmark of metastatic cancer; therefore, we used a transwell migration assay to determine whether the CD133 + PMC population can migrate. Compared with the CD133 − population of pituitary PMCs, the CD133 + shows a significant increase in migratory ability. Although this assay cannot determine whether the pituitary PMCs have undergone a transformation, it does demonstrate the potential for metastatic activity. The transplantation of CD133 + pituitary PMCs in immunodeficient mice will ascertain whether CD133-positive cells are tumorigenic.
Previously, Yunoue et al. 25 reported the identification of CD133positive cells in pituitary adenomas, especially in NS adenomas. Yunoue performed his research mainly on fixed tumors tissues and looked for a co-expression of CD34 and CD133. The expression of CD34 is in contradiction with the definition of MSCs that have to be negative for this hematopoietic marker. 7 Another difference deals with the changed expression of CD133 in GH + and NS adenomas. All our tumors were invasive macroadenoma with a similar pattern of extension and without any apparent difference a part from GH secretion. We did not find any significant difference between the two tumor types; this observation is in accord with Xu et al., 6 who reported a similar expression and behavior of cells derived both from GH + and NS adenomas. Also, Xu and colleagues 6 isolated a CD133 population from one GH + and one NS pituitary adenomas and, after serial transplantation into NOD/SCID mouse, they observed that cells were able to reform tumors.
The interaction of the cancer cells with stromal cells in the tumor microenvironment is essential for the progression of a tumor from a benign state to an invasive state. Stromal cells, especially carcinoma-associated fibroblasts, have received much attention for their role in the progression of tumors to a metastatic state. 36 Although pituitary PMCs are not fibroblast-derived, they may serve a similar function in pituitary adenomas. The interaction between transformed pituitary stem cells and pituitary PMCs may drive cancer progression in the pituitary.
In conclusion, our work offers original findings on the existence of undifferentiated PMCs in human pituitary tumors. PMCs isolated from three GH-secreting tumors and three NS tumors show superimposable features, such as morphology, doubling time population, immunophenotype, differentiative potential, gene expression and CD133 detection.The presence of this undifferentiated population in two separate pituitary adenomas suggests that pituitary PMCs may be common to all pituitary adenomas. We believe that two separate populations of stem cells exist within a pituitary adenoma, and future research that examines the interplay between these cell types may reveal important mechanisms of pituitary cancer progression.
